Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Enterprise Value (2016 - 2025)

Collegium Pharmaceutical has reported Enterprise Value over the past 10 years, most recently at -$251.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$251.1 million for Q4 2025, down 162.76% from a year ago — trailing twelve months through Dec 2025 was -$251.1 million (down 162.76% YoY), and the annual figure for FY2025 was -$251.1 million, down 162.76%.
  • Enterprise Value for Q4 2025 was -$251.1 million at Collegium Pharmaceutical, up from -$285.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for COLL hit a ceiling of -$95.6 million in Q4 2024 and a floor of -$325.5 million in Q2 2023.
  • Median Enterprise Value over the past 5 years was -$200.3 million (2021), compared with a mean of -$213.7 million.
  • Biggest five-year swings in Enterprise Value: crashed 165.21% in 2023 and later soared 69.23% in 2024.
  • Collegium Pharmaceutical's Enterprise Value stood at -$186.4 million in 2021, then increased by 6.83% to -$173.7 million in 2022, then tumbled by 78.8% to -$310.5 million in 2023, then soared by 69.23% to -$95.6 million in 2024, then crashed by 162.76% to -$251.1 million in 2025.
  • The last three reported values for Enterprise Value were -$251.1 million (Q4 2025), -$285.9 million (Q3 2025), and -$222.2 million (Q2 2025) per Business Quant data.